Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions

Authors: Chun-Hua Xu, Ping Zhan, Li-Ke Yu, Xiu-Wei Zhang

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Interleukin 17 (IL-17) has been found to be increased in some human cancers; however, the possible implication of IL-17 in regulating antitumor responses in lung cancer patients with malignant pleural effusions (MPE) remains to be elucidated. This study aimed to investigate the diagnostic value of pleural IL-17 and carcinoembryonic antigen (CEA) in MPE and benign pleural effusions (BPE). Pleural effusion samples from 108 patients were classified on the basis of diagnosis as MPE (n = 56) and BPE (n = 52). The concentration of IL-17 was determined by enzyme-linked immunosorbent assay (ELISA). The CEA levels were also determined in all patients. A significant difference was observed in the levels of CEA (P < 0.01) between MPE and BPE. The concentration of IL-17 in MPE was significantly higher compared to that in BPE (P < 0.01). With a cutoff point of 15.7 pg/ml, IL-17 had a sensitivity of 76.8 % and a specificity of 80.8 % for differential diagnosis. The combined detection of IL-17 and CEA had a sensitivity of 96.4 % and a specificity of 92.3 % to distinguish MPE from BPE. The combined detection of IL-17 and CEA may be more valuable in the differential diagnosis between MPE and BPE.
Literature
1.
2.
Cheng D, Liang B, Li YH. Application of MMP-7 and MMP-10 in assisting the diagnosis of malignant pleural effusion. Asian Pac J Cancer Prev. 2012;13:505–9.PubMedCrossRef
3.
Qian Q, Zhan P, Sun WK, Zhang Y, Song Y, Yu LK. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control. Neoplasma. 2012;59:433–9.PubMedCrossRef
4.
Darenskaia SD, Makarova NV, Vladimirskiĭ MA, Borisov SE, Emel'ianov MN, Kol'tsov KI, et al. Significance of determination of gamma-interferon in the diagnosis of tuberculous exudative pleurisy. Probl Tuberk Bolezn Legk. 2008;2:29–32.PubMed
5.
6.
Davies HE, Nicholson JE, Rahman NM, Wilkinson EM, Davies RJ, Lee YC. Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. Eur J Cardiothorac Surg. 2010;38:472–7.PubMedCrossRef
7.
Hiraki A, Aoe K, Eda R, Maeda T, Murakami T, Sugi K, et al. Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest. 2004;125:987–9.PubMedCrossRef
8.
Sriram KB, Relan V, Clarke BE, Duhig EE, Yang IA, Bowman RV, et al. Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol. 2011;7:737–52.PubMedCrossRef
9.
10.
Korczynski P, Krenke R, Safianowska A, Gorska K, Abou Chaz MB, Maskey-Warzechowska M, et al. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions. Eur J Med Res. 2009;4:128–33.CrossRef
11.
Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Carcinoembryonic antigen level in serum and pleural lavage fluid in non-small cell lung cancer. Thorac Cardiovasc Surg. 2010;58:350–3.PubMedCrossRef
12.
Ibrahim L, Salah M. Abd El Rahman A, Zeidan A, Ragb M. Crucial role of CD4+CD 25+ FOXP3+ T regulatory cell, interferon-γ and interleukin-16 in malignant and tuberculous pleural effusions. Immunol Investig. 2013;42:122–36.CrossRef
13.
Khaleeq G, Musani AI. Emerging paradigms in the management of malignant pleural effusions. Respir Med. 2008;102:939–48.PubMedCrossRef
14.
Yang HB, Shi HZ. T lymphocytes in pleural effusion. Chin Med J (Engl). 2008;121:579–80.
15.
Qin XJ, Shi HZ, Liang QL, Huang LY, Yang HB. CD4+CD25+ regulatory T lymphocytes in tuberculous pleural effusion. Chin Med J (Engl). 2008;121:581–6.
16.
Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457–64.PubMedCentralPubMedCrossRef
17.
Sfanos KS, Bruno TC, MarisCH X. L, Thoburn CJ, DeMarzo AM, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254–61.PubMedCentralPubMedCrossRef
18.
Miyahara YK, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A. 2008;105:15505–10.PubMedCentralPubMedCrossRef
19.
Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114:1141–19.PubMedCrossRef
20.
Wang T, Lv M, Qian Q, Nie Y, Yu L, Hou Y. Increased frequencies of T helper type 17 cells in tuberculous pleural effusion. Tuberculosis (Edinb). 2011;91:231–7.CrossRef
21.
Ye ZJ, Zhou Q, Zhang JC, Li X, Wu C, Qin SM, et al. CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res. 2011;12:77.PubMedCentralPubMedCrossRef
22.
Jin D, Chen Y, Wang Z, Wang S, Bunjhoo H, Zhu J, et al. Diagnostic value of interleukin 22 and carcinoembryonic antigen in tuberculous and malignant pleural effusions. Exp Ther Med. 2011;2:1205–9.PubMedCentralPubMed
23.
Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8:942–9.PubMedCrossRef
24.
Chen Z, O'shea JJ. Th-17 cells: a new fate for differentiating helper T cells. Immunol Res. 2008;41:87–102.PubMedCrossRef
25.
Spolski R, Lronard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 2008;26:57–79.PubMedCrossRef
26.
Aoe K, HirakI A, Yamazaki K, Nakamura Y, Murakami T, Maeda T, et al. Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients. Int J Oncol. 2006;29:65–72.PubMed
27.
Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion a meta-analysis. Respirology. 2008;13:518–27.PubMedCrossRef
Metadata
Title
Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions
Authors
Chun-Hua Xu
Ping Zhan
Li-Ke Yu
Xiu-Wei Zhang
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1220-2

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue

Research Article

Oxymatrine induces mitochondria dependent apoptosis in human osteosarcoma MNNG/HOS cells through inhibition of PI3K/Akt pathway

Research Article

miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor

Research Article

Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer?

Editorial

Comment on Zhou et al. entitled “High plasma d-dimer level is associated with decreased survival in patients with lung cancer: a meta-analysis based on current evidence”

Research Article

Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients

Research Article

Association between the cytotoxic T-lymphocyte antigen 4 +49A/G polymorphism and bladder cancer risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits